All In Biotech

Drug Trial Radar · NCT05427383

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.

Last checked: Nov 19, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Apr 7, 2022

Primary completion

Nov 2025

Study completion Nov 2026

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Jun 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together. Randomized stage is designed to evaluate the OS and PFS in patients receiving KN026 and chemotherapy compared to patients receiving placebo and chemotherapy.

Conditions

  • Stomach Cancer

Interventions

  • KN026/Placbo InjectionDrug

    IV KN026/Placebo at 30 mg/kg on D1, Q3W

  • Paclitaxel InjectionDrug

    IV Paclitaxel at 175 mg/m² on D1, Q3W

  • Docetaxel InjectionDrug

    IV Docetaxel at 75 mg/m² on D1, Q3W

  • Irinotecan InjectionDrug

    IV Irinotecan at 125 mg/m² on D1, D8, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) according to RECIST 1.1 by IRCTime frame: Up to 2.5 years
  2. Overall Survival (OS) according to RECIST 1.1 by IRCTime frame: Up to 2.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.